Bayer has awarded grants totaling more than $2 million to 16 recipients across eight countries as part of its Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from the Children's Hospital of Philadelphia and Uniformed Services University of the Health Sciences in Maryland are among the winners. Grant recipients were announced last night during a reception at the International Society on Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany. The BHAP grants will support research into a broad range of projects, including anxiety among female carriers of hemophilia, FVIII splicing-switching molecules for tailored hemophilia A therapies, and the assessment of therapeutic relationships in hemophilia care. The U.S. BHAP winners are:
The BHAP award recipients are selected by a global panel of hemophilia clinicians, researchers and caregivers. To date, BHAP has awarded more than 280 grants, totaling more than $33 million, to researchers and caregivers from 32 countries around the world and contributed to more than 400 publications, poster presentations and other scientific communications by awardees. To learn more about BHAP, visit the
website
.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.